Molecular Partners AG SEC filings MOLN
Molecular Partners AG has 121 filings in SEC EDGAR's recent list, going back to Mar 15, 2021. Its latest annual report, Form 20-F, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 17, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | May 2, 2025 | — |
| SC 13D/A | Amended ownership over 5% (active) | Oct 29, 2024 | — |
| SC 13D | Ownership over 5% (active) | Nov 20, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 7, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2023 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 12, 2022 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Jan 12, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Sep 15, 2021 | — |
Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MOLN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Schlieren-Zurich, Switzerland
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1745114
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.